 |
|
Duration of Hepatitis B Surface Antigenemia (HBs Ag) in Hemodialysis Patients
Seymour Ribot, MD;
Mitchell Rothstein;
Melvin Goldblat, MD;
Michael Grasso, MD
Arch Intern Med. 1979;139(2):178-180.
Abstract
Follow-up studies were done on 231 hemodialysis patients during a period of from one to 48 months to determine the natural history of hepatitis B surface antigenemia (HBs Ag). Of those studied, 113 (49%) exhibited HBs Ag. The probability of remaining HBs Ag positive over the mean follow-up period of 14.4 months was 62%. All of the 38 patients whose HBs Ag reverted to negative did so within ten months. Those patients whose HBs Ag reverted to negative had SGOT levels that were less frequently elevated than the patients with persistent antigenemia. Of hemodialysis patients with HBs Ag, 60% showed e antigen (HBe Ag).
(Arch Intern Med 139:178-180, 1979)
Author Affiliations
From Newark (NJ) Beth Israel Medical Center.
Footnotes
Accepted for publication Sept 1, 1978.
Reprint requests to Newark Beth Israel Medical Center, 201 Lyons Ave, Newark, NJ 07112 (Dr Ribot).
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Seroconversion rate to positivity for antibodies against core antigen of hepatitis B virus and duration of renal replacement therapy
Grzegorzewska et al.
Nephrol Dial Transplant 2011;26:970-976.
ABSTRACT
| FULL TEXT
Hepatitis B Virus in Patients Undergoing Hemodialysis: Transmission Risks and Psychosocial Reactions
Kiernan and Powers
Arch Intern Med 1982;142:51-54.
ABSTRACT
|
